Eli Lilly Highlights Results from the P-III Study of Lebrikizumab for People with Skin of Color and Moderate-to-Severe Atopic Dermatitis at AAD’24
Shots:
- The 24 wk. P-IIIb (ADmirable) trial assesses lebrikizumab’s (500mg, SC, initially & at 2wks. followed by 250mg, Q2W until wk. 16) safety & efficacy in patients (n=50) with moderate-to-severe atopic dermatitis & skin of color. It also includes physician evaluation of post-inflammatory pigmentation changes by the PDCA-Derm scale
- The results at 16 wks. demonstrated EASI-75 in 68%, EASI-90 in 46%, clear/almost clear skin with a reduction of ~2 points from baseline in 39% & itch relief in 55% of patients. Full data is anticipated in future conferences
- Lilly holds the exclusive worldwide (excl. the EU) development & commercialization rights for lebrikizumab & Almirall has its development & commercialization rights in the EU
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Almirall Received EC’s Approval for Ebglyss (lebrikizumab) to Treat Moderate-to-severe Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
